Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride (Cis Z isomer) changes leaving the study early: Any reason compared with zuclopenthixol (Cis Z/Trans E isomer) (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Duration of grade IV neutropenia (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in duration of grade IV neutropenia (lower values signify better… compared with antibiotics alone (low certainty).
1 finding from 1 review
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes serious adverse events maximum compared with standard care (very low certainty).
1 finding from 1 review
Neurological developmental impairment maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes neurological developmental impairment maximum compared with standard care (very low certainty).
1 finding from 1 review
Necrotising enterocolitis maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes necrotising enterocolitis maximum compared with standard care (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).
1 finding from 1 review
Clinically significant response on psychotic symptoms ‐ as defined by each of the studies. · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects, general and specific · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Average change in quality of life/satisfaction · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically significant response on global state · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in sedation/tranquillisation: Not sedated ‐ at four hours compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in global state: 1. Requiring supplementary medication ‐ antipsychotics compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE may leads to lower global state: 2. Requiring 3 or more injections ‐ over 7 days compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in mental state: 1. No important improvement compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia during 24 hours · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in adverse effects: Movement disorders ‐ dystonia (spasmodic postural… compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Resolution of symptoms Not measured · patients with trigger finger
The review found no eligible studies for this question.
3 findings from 1 review